Results 41 to 50 of about 10,221 (208)

Aggressive giant prolactinoma: a case report

open access: yesJournal of Medical Case Reports, 2022
Background Managing treatment-resistant aggressive giant prolactinoma can be challenging, as the diagnosis is often complex, and treatment beyond dopamine agonists, surgery, and radiotherapy is limited.
Marisa Khatijah Borhan   +1 more
doaj   +1 more source

Continuous outcome estimation in N‐of‐1 trials for accelerated decision‐making

open access: yesEpilepsia, EarlyView.
Abstract Objective N‐of‐1 trials aim to determine the therapeutic effect for a single individual. This individualized approach necessitates collecting multiple data points over time through repeated alternating periods of active treatment and a comparator or control condition.
Victoria Defelippe   +5 more
wiley   +1 more source

Relationship between prolactin plasma levels and white matter volume in women with multiple sclerosis [PDF]

open access: yes, 2015
BACKGROUND: The role of prolactin (PRL) on tissue injury and repair mechanisms in multiple sclerosis (MS) remains unclear. The aim of this work was to investigate the relationship between PRL plasma levels and brain damage as measured by magnetic ...
Barletta, VALERIA TERESA   +10 more
core   +4 more sources

Status epilepticus induced by treatment with dopamine agonist therapy for giant prolactinoma: a case report

open access: yesJournal of Medical Case Reports, 2019
Background Dopamine agonists are the standard first-line medical therapy for prolactinoma. We report a rare case of giant prolactinoma with a first epileptic seizure due to rapid reduction of the tumor as a complication of dopamine agonist therapy.
Motofumi Koguchi   +6 more
doaj   +1 more source

Kisspeptin as a test of hypothalamic dysfunction in pubertal and reproductive disorders

open access: yesAndrology, EarlyView.
Abstract The hypothalamic–pituitary–gonadal axis is regulated by the gonadotropin‐releasing hormone pulse generator in the hypothalamus. This is comprised of neurons that secrete kisspeptin in a pulsatile manner to stimulate the release of GnRH, and, in turn, downstream gonadotropins from the pituitary gland, and subsequently sex steroids and ...
Aureliane C. S. Pierret   +5 more
wiley   +1 more source

Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels. [PDF]

open access: yes, 2013
OBJECTIVE: Currently available studies that fully analyse the metabolic parameters in patients with prolactinoma are scarce and discordant. The aim of this study was to evaluate the metabolic effects of cabergoline (CAB) treatment in patients with newly
AMATO, Marco Calogero   +4 more
core   +1 more source

Very Long‐Term Follow‐Up of Multidimensional Health‐Related Quality of Life After Endoscopic Endonasal Surgery for Pituitary Adenomas: A Prospective Cohort Study

open access: yesHead &Neck, Volume 48, Issue 4, Page 1088-1096, April 2026.
ABSTRACT Background To evaluate postoperative health‐related quality of life (HRQoL) for pituitary adenoma patients, multidimensional assessment is important. Available data is limited on long‐term follow‐up. Methods Prospectively, 52 nonfunctioning (NFA) and functioning (FA) pituitary adenoma patients were included.
Gonneke E. Joustra   +7 more
wiley   +1 more source

Exploring retinal vessel density alterations in prolactinoma patients: Insights from OCTA imaging

open access: yesIndian Journal of Ophthalmology
Purpose: To investigate microvascular changes in the macular and peripapillary area in prolactinoma patients by using optical coherence tomography angiography (OCTA). Design: A retrospective study.
Serife Ciloglu Hayat   +3 more
doaj   +1 more source

Management of prolactinoma during pregnancy and postpartum

open access: yesJournal of Integrated Health Sciences, 2015
Prolactinoma is classified as microprolactinoma when it measures
Om J Lakhani   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy